INTRODUCTION
============

Chronic kidney disease (CKD) is a public health problem in Mexico and is associated with an increased mortality and substantial health care costs.^[@bib1],\ [@bib2]^ Approximately 8% of the Mexican adult population has CKD,^[@bib3]^ and the prevalence is twofold higher in high-risk populations.^[@bib4],\ [@bib5]^ Given these exceedingly high prevalence rates, early detection and management of CKD could have a significant impact at the population level because timely intervention can decrease the incidence of cardiovascular disease and progressive kidney function loss in this population.^[@bib6]^

Owing to the complexity of care of patients with CKD, it has been recommended that a coordinated multidisciplinary approach could improve management and outcomes in this population.^[@bib7]^ Multidisciplinary clinics have been shown to be associated with reduced morbidity and mortality (once on dialysis) in patients with CKD stages 4 and 5---potentially due to more intensive management of diabetes, hypertension, mineral metabolism and timely vascular access creation.^[@bib8],\ [@bib9]^ In a large study of 6978 elderly outpatients with CKD, multidisciplinary care (MDC) was associated with a significant reduction in the risk for all-cause mortality and a trend toward a reduction in risk for hospitalizations.^[@bib10]^ Additionally, MDC has been shown to reduce costs without compromising the quality of life of patients with CKD.^[@bib11]^

In 2005, our institutions entered into a partnership aimed at preventing kidney failure in the poor of the state of Jalisco, Mexico. The objective of this collaboration is to reduce morbidity and mortality caused by kidney failure by identifying CKD and risk factors for cardiovascular disease in this population. Different strategies have been used to identify cases, including screening in public places on World Kidney Day^[@bib12],\ [@bib13]^ and promoting awareness of kidney disease among local primary care physicians. Additionally, since 2006, we have screened people at risk of the presence of CKD using mobile units that travel to poor rural and urban communities.^[@bib4],\ [@bib5]^ Patients with CKD identified in this way are referred to a nurse-coordinated, protocol-driven, MDC clinic. Established in 2008, the clinic provides subsidized care to eligible patients without social security or private medical insurance. In this study, we report the results of this program between March 2008 and July 2011.

METHODS
=======

The MDC clinic
--------------

Our clinic\'s operating procedures ([Table 1](#tbl1){ref-type="table"}) are based on the multidisciplinary model of the University of Alberta\'s MDC Clinic, Edmonton, Canada.^[@bib10]^ The clinic is located at the Hospital Civil de Guadalajara, a tertiary care facility that offers comprehensive renal care to the uninsured population of the state of Jalisco. Since 2006, six nephrology fellows from our center have received training in MDC during rotations in Edmonton.

Patients are referred to the clinic by their physicians, other nephrologists, or by the staff of the Fundacion Hospitales Civiles\' mobile units. At the first visit, an education session is held with the patient and his or her family members and is attended by a specialized clinic nurse, registered dietician, and nephrologist. Patient education includes a discussion of CKD and its progression and complications, fluid and dietary restrictions, monitoring BP, effects of medications, and recommendations regarding exercise and diet. MDC patients undergo clinical evaluation and blood work every 1 to 3 months, as determined by nephrologist and nurse, to monitor kidney function and metabolic complications. Management in the MDC clinic is focused on medical management and lifestyle modification to delay progression of CKD and target cardiovascular risk factor reduction. Except for erythropoietin, all medications are provided free of cost by Seguro Popular,^[@bib14]^ a national health insurance program for the uninsured (poor urban and rural communities, self-employed, and informal workers).

Data source and study population
--------------------------------

We reviewed the medical records of 676 patients referred to the clinic between March 2008 and July 2012. Data were collected prospectively by the staff of the clinic using a standardized form. Patients with CKD stage 5 (*n*=94), those with incomplete data (*n*=90), lost to follow-up after the first visit (*n*=123), and patients \<18 years old (*n*=16), were excluded from this report. Only patients with CKD stage 3 and 4, with at least one follow-up visit, were included in the analysis. Baseline data obtained from each patient included age, sex, employment and marital status, education level, smoking status, alcohol use, diabetic status, and personal history of diabetes or hypertension. At each visit, height and weight were measured and used to calculate body mass index. Systolic and diastolic blood pressures were measured using manual sphygmomanometers after patients rested quietly for 5 min. Results of serum creatinine, calcium, phosphate, albumin, total cholesterol, triglycerides, glucose, HgbA1c, urinalysis, and hemoglobin levels, were entered in the medical record. Parathyroid hormone measurement was not available and HgbA1c was measured in only 24% of the patients due to financial constraints.

Definitions
-----------

Results of dipstick urinalysis demonstrating ⩾1+ protein were considered to indicate proteinuria. Hypertension was classified according to the Joint National Committee 7 scheme.^[@bib15]^ Patients were classified as having diabetes mellitus if they gave a history of diabetes or had a fasting blood glucose level \>126 mg/dl. Levels of total cholesterol and fasting triglycerides were classified according to published guidelines.^[@bib16]^ Serum creatinine was used to calculate estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD). Study equation and CKD was classified according to NKF-K/DOQI guidelines.^[@bib17]^ Normal values of serum calcium and phosphate for adults in our program were 8.4--10.2 mg/dl and 2.7--4.6 mg/dl, respectively.

Study outcomes
--------------

Assessment of quality of care parameters for management of blood pressure, anemia, glycemic, lipids, and mineral disorder in CKD was done following published NKF-K/DOQI and KDIGO guidelines^[@bib18],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^

Statistical analysis
--------------------

Characteristics of patients with CKD stages 3 and 4, as well as differences between baseline and follow-up variables were compared with χ^2^-tests for categorical variables and *t*-test for continuous variables. A *P*-value \<0.05 was considered statistically significant. All analysis were conducted with SPSS (version 15.0).

RESULTS
=======

A total of 353 patients with CKD stage 3 (*n*=175) and stage 4 (*n*=178) were followed for a mean of 14.2 months (range 0.8--40.2 months) ([Table 2](#tbl2){ref-type="table"}). Mean age was 59.1±15.5 years; 54.4% were female and 63.7% were diabetic; at baseline, serum creatinine and eGFR were 2.29±0.86 mg/dl and 31.7±11.9 ml/min per 1.73 m^2^, respectively; 52.9% had urine protein ⩾1+ systolic blood pressure ⩾140 mm Hg or diastolic blood pressure ⩾90 mm Hg was present in 56.3% of the patients and 23% had a blood pressure \<130/80 mm Hg. In all, 36.4% had a serum glucose \>126 mg/dl; HgbA1c levels measured at baseline were available in 86 diabetic patients and it was \<7.0% in 26.4% of them. Average hemoglobin was 11.8±1.8 g/dl and 27.7% had hemoglobin \<11 g/dl. Hyperuricemia was present in 46.3% of the patients. Dyslipidemia was highly prevalent; serum cholesterol ⩾160 mg/dl, and serum triglycerides \>500 mg/dl, were present in 66% and 2.1% of patients, respectively. Female gender (60.7% vs. 48%, *P*=0.01), serum hemoglobin \<11.0 g/dl (37.5% vs. 17.6%, *P*=0.001), hypocalcemia (26.3% vs. 15.1%, *P*=0.03), and proteinuria (61% vs. 44%, *P*=0.003) were more prevalent in patients with CKD stage 4 than in stage 3.

Pre- and post-intervention results are presented in [Table 3](#tbl3){ref-type="table"}. There were significant changes in the quality of care parameters between baseline and the final visit. Use of angiotensin II receptor blockers (ARB) and beta blockers increased from 30.6% to 46.6% (*P*=0.001) and from 11% to 19% (*P*=0.003), respectively; insulin and statin use increased from 65.0% to 74.3% (*P*=0.001) and from 41.4% to 80.3% (*P*=0.001), respectively; the use of hypoglycemic agents did not significantly differ (16.8% vs. 17.3%, *P*= 0.89); allopurinol, erythropoietin, and calcium binders use increased from 20.7% to 63.1% (*P*=0.001), from 10.5% to 23.4% (*P*=0.001), and from 41.9% to 82.6% (*P*=0.001), respectively. At last visit, 66% of patients were taking ACE inhibitors (ACEI) and 90% were taking either ARB or ACEI.

Mean arterial blood pressure decreased from 101±18 mm Hg at referral to 94±18 mm Hg (*P*=0.001) at last visit. Systolic blood pressure ⩾140 mm Hg or diastolic blood pressure ⩾90 mm Hg decreased from 56.3% to 46.4% (*P*=0.01) and blood pressure \<130/80 mm Hg increased from 23% to 38% (*P*=0.001). In diabetic patients, serum glucose decreased from 149±78 mg/dl to 130±73 mg/dl (*P*=0.005) and serum glucose ⩽130 mg/dl increased from 54.4% to 67.7% (*P*=0.0001). The proportion of HgbA1c \<7.0% did not significantly differ (25.6% vs. 31.4%, *P*=0.52). Serum cholesterol decreased from 188±59 mg/dl to 178±53 mg/dl (*P*=0.003), but the proportion with serum cholesterol \>160 mg/dl did not significantly differ (64.8% vs. 60.3%, *P*=0.30). At last visit, 70% of the patients had hemoglobin ⩾11.0 g/dl, and 80.1% and 65.1% had a serum calcium and phosphate within the normal range, respectively. Uric acid decreased from 6.88±2.06 mg/dl to 6.43±1.92 mg/dl (*P*=0.001), and the proportion of patients with hyperuricemia decreased from 46.3% to 37.0% (*P*=0.02). Proteinuria in nondiabetic (47.8% vs. 45.8%, *P*=0.86) and diabetic patients (55.7% vs. 56.2%, *P*=0.99) did not significantly differ.

DISCUSSION
==========

Our findings suggest that a coordinated MDC could improve management and outcomes in poor CKD patients treated in a developing country. Blood pressure control is a major tool for improving outcomes in patients with CKD; our data demonstrate the potential value of the MDC care for achieving this objective. Despite the increase in the proportion of patients with controlled blood pressure, the majority (62%) remained above the target of \<130/80 mm Hg as recommended by the NKF-K/DOQI;^[@bib18]^ this findings are similar to those reported by Thanamayooran *et al.*^[@bib23]^ and demonstrate the difficulty in achieving target blood pressure even in an optimal clinic environment. The proportion of patients with proteinuria was similar at follow-up and baseline. However, as we did not use a quantitative method to measure protein excretion, we could not assess the impact of treatment on proteinuria. The average decline in eGFR was −3.8 ml/min per 1.73 m^2^ in diabetic patients, but did not change in nondiabetic individuals, which compares favorably with the average rate of kidney function loss as reported by others.^[@bib24],\ [@bib25]^

Hemoglobin levels did not change over time. At last visit, mean Hgb was 11.8±1.8 g/dl, and the proportion of patients meeting the NKF-K/DOQI^[@bib19]^ target of Hgb 11.0--12.0 g/dl at baseline and at follow-up was 30%. Although erythropoietin prescription doubled at follow-up in comparison with the baseline, the majority (77%) of the patients did not receive treatment even after visiting the clinic---likely because of the high cost of this medication.

Calcium control was generally good. The proportion of patients with normal calcium levels rose from 76% at baseline to 80% at last visit. At baseline, hypocalcemia was present in 21% of patients and decreased to 17.6% at last visit, but it did not reach statistical significance. Phosphate control was more difficult to obtain; one-third of the patients had hyperphosphatemia at baseline and did not change at follow-up despite the increase in calcium-binders prescription. Glycemic control improved over time; 67.7% of diabetic patients reached the NKF-K/DOQI^[@bib20]^ guideline target of serum glucose ⩽130 mg/dl, compared with 50.4% at baseline. However, HgbA1c \<7.0% was achieved in only 30% of 86 patients at last visit. Uric acid levels decreased significantly at the end of the study. Targeting increased uric acid levels has been shown to slow CKD progression and decrease cardiovascular risk.^[@bib26],\ [@bib27]^ Despite a significant increase in statin prescription, two-thirds of patients had serum cholesterol \>160 mg/dl at follow-up. Whether this was due to poor compliance with medications could not be ascertained.

A significant proportion of patients (23%) were lost to follow-up. Although we did not investigate the reason for dropping out of the program, one possibility is that they cannot afford the expense of traveling to the clinic. Indeed, we have previously reported that many of our dialysis patients abandon their treatment because of the expense of commuting to our hospital.^[@bib28]^ Finally, six patients electively started CAPD, two hemodialysis, and two received living-donor kidney transplants. Five of our patients died at home on follow-up, but the cause of death could not be determined.

Our study has several limitations. First, the length of follow-up was relatively short between the intervention and evaluation of quality targets achieved; therefore, we could not assess the impact of intervention on decline of eGFR or other clinically relevant outcomes, such as mortality and cardiovascular events. Second, although data were collected prospectively, they may not be generalizable to all low-income settings or other regions of Mexico. Third, we used dipstick urinalysis rather than timed urine collection or albumin--creatinine ratios to assess proteinuria; therefore, the prevalence of proteinuria may have been overestimated and did not allow us to assess the impact of treatment. Fourth, the limited availability of HgbA1c measurement did not allow us to properly assess the impact of treatment on diabetes control. Fifth, the MDRD Study equation has not been validated specifically in an unselected Mexican population; therefore, some participants may have been misclassified with respect to the presence or absence of eGFR \<60 ml/min per 1.73 m^2^ or ⩾15 ml/min per 1.73 m^2^ Sixth, the lack of a control (standard care) group did not allow us to determine if the results are attributable to the MDC alone or to other factors. Finally, although it is tempting to speculate that intervention in people found to have CKD would improve clinical outcomes, there currently are few data from randomized trials to support this hypothesis. We tried to focus on a broad range of quality parameters as recommended by internationally accepted guidelines---but it is important to note that the underlying evidence is stronger for some objectives (such as, blood pressure control, use of ACEI/ARB, and use of statins) than for the others.

In summary, our results showed a similar trend in improvement of quality of care parameters as those reported by other MDC programs in the developed world.^[@bib23],\ [@bib24],\ [@bib29]^ Our study demonstrates that nurse-led MDC programs could be successfully implemented in developing countries, and could help to improve clinical outcomes. Although our results suggests that the components of MDC programs may improve care for patients with CKD, further research is needed to evaluate the program component effectiveness in CKD prevention and management.
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###### Operating procedures

  **Team member**          **Intervention**
  ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nurse (30 min)           Retrieval of the patient from waiting area
                           Documentation of patient demographic information
                           Etiology of CKD
                           Identification of risk factors for CKD progression
                           Calculation of patient eGFR
                           Estimation of start RRT and review modality plan if eGFR \<20 ml/min per 1.73 m^2^
                           Measurement of vital signs, blood pressure, height and weight
                           Review of symptoms (uremic, cardiac, respiratory)
                           List antihypertensive treatment, dosage and frequency
                           Fluids: evaluation of volemic status
                           Glycemic control: review ambulatory glycemic record, medications and hypo-hyperglycemic episodes
                           Anemia: review of symptoms related to anemia; implementation of anemia protocol if necessary
                           Review of medication, dosage, frequency, interactions
                           Record blood and urine tests
                           Review of all recommendations regarding CKD progression, RRT modality plan, treatment goals, blood pressure control, anemia, mineral metabolism
                           Instructions for routine blood and urine tests, future appointments
  Dietician (30 min)       Review of clinic blood work for K^+^, Ca, PO4, albumin, hemoglobin, uric acid, hemoglobin, cholesterol, triglycerides, HgbA1c targets
                           Anthropometric evaluation; weight changes
                           Review of dietary habits
                           Discussion of dietary changes with emphasis on protein, K^+^, sodium, carbohydrates, PO~4~, and lipids intake; use of PO~4~ binders, Vitamin D, and iron supplements
  Physician (30 min)       Review of clinic blood work for K^+^, Ca, PO~4~, albumin, hemoglobin, uric acid, hemoglobin, cholesterol, triglycerides, HgbA1c targets
                           Evaluation of hypertension, anemia, Ca^+^, PO~4~, lipids therapy in an algorithmic fashion
                           Anemia management recommendations
                           Assessment of medication adherence and barriers to compliance
                           Review of all recommendations regarding CKD progression
                           Review of RRT modality and treatment plan
                           Request (based on modality plan) vascular access consults, peritoneal dialysis suitability, transplant assessments
  Social worker (30 min)   Evaluation of social and economic factors; employment; family support
                           Review of charitable and welfare organizations that provide services to CKD patients

Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy.

###### Demographics and clinical characteristics of study participants

                                                  **All (*n*=353)**   **CKD stage 3 (*n*=175)**   **CKD stage 4 (*n*=178)**  ***P*-value**
  ---------------------------------------------- ------------------- --------------------------- --------------------------- ---------------
  Age (years)                                         59.1±15.5               60.7±15.8                   57.5±15.1          0.05
  *Gender (%)*                                                                                                               0.01
   Male                                              141 (45.6)                91 (52)                    70 (39.3)           
   Female                                            192 (54.4)                84 (48)                   108 (60.7)           
                                                                                                                              
  Diabetics (%)                                      225 (63.7)              114 (65.1)                   111(62.4)          0.32
  Height (m)                                          1.59±0.9                 1.6±0.9                     1.5±0.9           0.65
  Weight (kg)                                         66.8±14.4               67.0±14.9                   66.7±13.9          0.84
  Body mass index (kg/m^2^)                           26.0±5.1                25.7±5.0                    26.4±5.26          0.21
  Serum creatinine (mg/dl)                            2.29±0.86               1.70±0.55                   2.86±0.72          0.001
  eGFR (ml/min per 1.73 m^2^)                         31.7±11.9               41.6±8.6                    21.9±4.2           0.001
  Systolic blood pressure (mm Hg)                      146±30                  146±31                      146±30            0.97
  Diastolic blood pressure (mm Hg)                      79±14                   78±15                       80±14            0.36
  SystBP⩾140 or diastBP ⩾90 mm Hg (%)                197 (56.3)               98 (56.0)                   99 (55.6)          1.00
  *Hemoglobin (g/dl)*                                 11.8±1.8                12.5±1.8                    11.2±1.7           0.001
   \<11 g/dl                                          96 (27.7)               30 (17.6)                   66 (37.5)          0.001
                                                                                                                              
  *Serum glucose (mg/dl)*                              130±68                  129±58                      132±77            0.72
   \>126 mg/dl (%)                                   124 (36.4)               65 (38.2)                   59 (34.5)          0.50
   ⩽130 mg/dl (%)                                    229 (67.2)              109 (64.1)                  120 (70.2)          0.25
                                                                                                                              
  *HgbA1c (%)*[a](#t2-fna){ref-type="fn"}              8.5±2.3                 8.6±2.2                     8.4±2.4           0.82
   \<7.0 (%)                                          20 (25.6)               32 (86.5)                   26 (63.4)          0.03
                                                                                                                              
  *Total cholesterol (mg/dl)*                          188±55                  185±52                      186±57            0.81
   ⩾160 mg/dl                                        182 (64.8)               95 (66.0)                   87 (63.5)          0.70
                                                                                                                              
  *Triglycerides (mg/dl)*                              186±128                 190±143                     182±110           0.59
   ⩾500 mg/dl                                          5 (1.8)                 3 (2.1)                     2 (1.5)           1.00
  Serum albumin (g/dl)                                 3.5±0.6                 3.6±0.6                     3.5±0.6           0.14
  Serum uric acid (mg/dl)                             6.86±2.0                6.75±1.89                   6.97±2.22          0.33
  Hyperuricemia (%)[b](#t2-fnb){ref-type="fn"}       150 (46.3)               77 (46.4)                   73 (46.2)          0.53
                                                                                                                              
  *Serum calcium (mg/dl)*                              8.9±0.8                 8.9±0.9                     8.8±0.7           0.21
   Within normal range (%)                           169 (76.8)               85 (80.2)                   84 (73.7)          0.26
   \<8.4 mg/dl                                        46 (20.9)               16 (15.1)                   30 (26.3)          0.04
                                                                                                                              
  *Serum phosphate (mg/dl)*                            4.3±0.8                 4.2±0.9                     4.4±0.7           0.21
   Within normal range (%)                           125 (67.2)               58 (66.7)                   67 (67.7)          1.00
   \>4.6 mg/dl                                        57 (30.6)               25 (28.7)                   32 (32.2)          0.63
                                                                                                                              
  Proteinuria (%)                                    171 (52.9)               69 (44.2)                  102 (61.1)          0.003

Abbreviations: diastBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; systBP, systolic blood pressure.

HgbA1c was measured only in diabetic patients.

\>6.5 mg/dl in females and \>7.5 mg/dl in males.

###### Quality of care parameters

                                                            **Baseline (*n*= 353)**   **Last visit (*n*= 353)**  ***P*-value**
  -------------------------------------------------------- ------------------------- --------------------------- ---------------
  Systolic blood pressure (mm Hg)                                   146±30                     137±30            0.0001
  Diastolic blood pressure (mm Hg)                                  79 ±14                      71±15            0.0001
  MAP mm Hg                                                         101±18                      94±18            0.0001
  SystBP⩾140 mm Hg or diastBP⩾90 mm Hg                            197 (56.3)                 162 (46.4)          0.01
  Blood pressure \<130/80 mm Hg (%)                                81 (23.1)                  132(37.8)          0.0001
  HTN on treatment (%)                                            182 (91.5)                  199 (100)          0.0001
  HTN treatment and controlled (%)                                 26 (14.4)                  62 (31.5)          0.0001
  BMI (kg/m^2^)                                                    26.0±5.1                   25.8±5.4           0.17
  *Hemoglobin (g/dl)*                                              11.8±1.9                   11.8±1.8           0.98
   \<11 g/dl (%)                                                   96 (27.7)                 104 (30.0)          0.57
                                                                                                                  
  *Blood glucose (mg/dl)*[a](#t3-fna){ref-type="fn"}                149±78                     130±73            0.005
   ⩽130 mg/dl (%)[a](#t3-fna){ref-type="fn"}                      114 (50.4)                 153 (67.7)          0.0001
                                                                                                                  
  *HgbA1c (%)*[a](#t3-fna){ref-type="fn"}                           8.5±2.0                    7.8±1.6           0.03
   \<7.0 (%)                                                       20 (25.6)                  27(31.4)           0.52
                                                                                                                  
  *Total cholesterol (mg/dl)*                                       188±59                     178±53            0.003
   \>160 mg/dl (%)                                                182 (64.8)                 190 (60.3)          0.30
                                                                                                                  
  Triglycerides (mg/dl)                                             187±130                    174±115           0.11
   \>500 mg/dl (%)                                                  5 (1.8)                   10 (3.1)           0.44
                                                                                                                  
  *Serum uric acid (mg/dl)*                                        6.88±2.06                  6.43±1.92          0.001
   Hyperuricemia (%)[b](#t3-fnb){ref-type="fn"}                   150 (46.3)                 120 (37.0)          0.02
                                                                                                                  
  Serum albumin (g/dl)                                              3.5±0.6                    3.5±0.7           0.37
  *Serum calcium (mg(dl)*                                           8.9±0.9                    8.9±0.7           0.46
   Within normal range (%)                                        169 (76.8)                 218 (80.1)          0.43
   \<8.4 mg/dl                                                     46 (20.9)                  48 (17.6)          0.42
                                                                                                                  
  *Serum phosphate (mg/dl)*                                         4.3±0.8                    4.4±1.0           0.74
   Within normal range                                            125 (67.2)                  166(65.1)          0.72
   \>4.6 mg/dl                                                     57 (30.6)                  82 (33.3)          0.81
  Serum creatinine (mg/dl)                                         2.29±0.86                  2.8±1.70           0.000
  eGFR (ml/min per 1.73 m^2^)[c](#t3-fnc){ref-type="fn"}           32.4±13.0                  32.4±17.0          0.43
  eGFR (ml/min per 1.73 m^2^)[a](#t3-fna){ref-type="fn"}           31.3±11.3                  27.5±15.3          0.000
  Proteinuria non-DM (%)                                           54 (47.8)                  54 (45.8)          0.86
  Proteinuria DM                                                  117 (55.7)                 122 (56.2)          0.99
  Insulin use (%)[a](#t3-fna){ref-type="fn"}                      147 (65.0)                 168 (74.3)          0.02
  Oral hypoglycemics use (%)[a](#t3-fna){ref-type="fn"}            38 (16.8)                  39 (17.3)          0.89
  ACEI use (%)                                                    243 (68.8)                 232 (66.3)          0.52
  ARB use (%)                                                     108 (30.6)                 163 (46.6)          0.001
  Beta blockers use (%)                                            39 (11.0)                  67 (19.0)          0.003
  Aspirin use (%)                                                  94 (26.7)                  91 (26.0)          0.89
  Statin use (%)                                                  146 (41.4)                 281 (80.3)          0.001
  Allopurinol use (%)                                              73 (20.7)                 221 (63.1)          0.001
  EPO use (%)                                                      37 (10.5)                  82 (23.4)          0.001
  Calcitriol use (%)                                               10 (2.8)                    6 (1.7)           0.41
  Calcium binders (%)                                             148 (41.9)                 289 (82.6)          0.001

Abbreviations: ACEI, ACE inhibitor; ARB, angiotensin II receptor blockers; BMI, body mass index; BP, blood pressure; diastBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration; EPO, erythropoietin; MAP, mean arterial blood pressure; systBP, systolic blood pressure.

Diabetic patients only.

Nondiabetic patients.

\>6.5 mg/dl in females and \>7.5 mg/dl in males.
